Advanced search

794 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transcript : Hingham Institution for Savings - Shareholder/Analyst Call	Apr. 25
The Taiwan Fund, Inc. Announces the Results of the Annual Stockholders Meeting	Apr. 24	PR
Pembina Pipeline : About Pembina Pipeline Corporation - Form 6-K	Mar. 28	PU
Kirby : 2024 Proxy Statement	Mar. 11	PU
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa	Mar. 10	BU
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day	Mar. 10	AQ
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day	Mar. 10	GL
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024	Mar. 04	GL
Canadian Natural Resources Limited Announces 2023 Fourth Quarter and Year End Results	Feb. 29	NE
Kirby McInerney LLP Reminds Hut 8 Corp. (HUT) Investors of Class Action Filing and Encourages Investors to Contact the Firm	Feb. 23	BU
OceanaGold Reports Mineral Reserves and Resources for the Year Ended 2023	Feb. 21	AQ
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Hut 8 Corp. (HUT) Investors	Feb. 08	BU
Kirby Corporation Announces 2023 Fourth Quarter and Full Year Results	Feb. 01	GL
Kirby Corporation Announces 2023 Fourth Quarter and Full Year Results	Feb. 01	AQ
Kirby Corporation Announces Management Changes, Effective April 26, 2024	Feb. 01	CI
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Hut 8 Corp. (HUT)	Jan. 23	BU
European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer	Jan. 08	BU
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Microvast Holdings, Inc. (MVST) Investors and Encourages Investors to Contact the Firm Before February 5, 2024	Dec. 22	BU
Bellicum Pharmaceuticals : 3730 Kirby Drive, Ste. 1200 Houston, TX 77098 - Form 8-K	Dec. 14	PU
OceanaGold Continues to Delineate High-Grade Gold Mineralization at Haile and Wharekirauponga	Dec. 14	AQ
Canadian Natural Resources Limited Announces 2024 Budget	Dec. 14	NE
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Microvast Holdings, Inc. (MVST) Investors	Dec. 08	BU
Transcript : Washington H. Soul Pattinson and Company Limited - Shareholder/Analyst Call	Dec. 07
Vaso Corporation entered into a business combination agreement to acquire Achari Ventures Holdings Corp. I from Achari Sponsor Holdings I LLC and others for approximately $190 million in a reverse merger transaction.	Dec. 06	CI
Canadian Natural Resources Limited Announces 2023 Third Quarter Results	Nov. 02	NE
OceanaGold : Q3 2023 MD&A	23-10-25	PU
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa	23-10-16	AQ
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa	23-10-15	AQ
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa	23-10-15	GL
UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023	23-10-13	CI
Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)	23-10-13	BU
Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa	23-10-12	PR
UCB : Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa	23-10-12	PU
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress	23-10-11	GL
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress	23-10-11	AQ
Severance Denied: Diag Human v Volterra Fietta [2023] EWCA Civ 1107; A Potential Public Policy Warning For Litigation Funders	23-10-11	AQ
The Legal Landscape Following The Supreme Court's Decision In PACCAR	23-10-10	AQ
UCB : to Present New Bimekizumab Data in Hidradenitis Suppurativa, Psoriasis and Psoriatic Arthritis at EADV 2023	23-10-09	PU
Phase 2 MIRA primary analysis trial results for MoonLake's Nanobody sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress	23-10-05	AQ
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress	23-10-04	AQ
OceanaGold Mines First Ore from Horseshoe Underground and Provides Haile Operations and Exploration Update	23-09-14	AQ
Kyodo News Digest: Aug. 31, 2023 -1-	23-08-30	AQ
Canadian Natural Resources Limited Announces 2023 Second Quarter Results	23-08-03	NE
OceanaGold : Q2 2023 MD&A	23-08-01	PU
CVS Health Corporation Appoints Scott Kirby to Board of Directors, Effective October 1	23-07-20	CI
Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval	23-06-20	BU
ICML 2023 Meeting: CFT7455 in NHL Preclinical Presentation	23-06-16	PU
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Cutera, Inc. (CUTR) Investors and Encourages Investors to Contact the Firm Before July 24, 2023	23-06-02	BU
Lynparza plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer	23-06-01	AQ
LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer	23-06-01	BU

No results for this search

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer